The company's principal activity is the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers. The company's products are developed utilizing the reovirus for treatment of cancers in humans. The reovirus has been demonstrated to replicate specifically in tumor cells bearing an activated ras pathway. Activating mutations of ras and mutations along the("Activated") ras pathway occur in approximately 65% of all tumors. The company's technologies are based on discoveries made in the department of microbiology and infectious diseases at the university of calgary.
